PEMGARDA® (pemivibart) net product revenue of $13.1 million reported for Q3 2025, representing 41$100 million; ended Q3 2025 with $85.0 million in cash and cash equivalents after closing of$57.5 million public offering in August 2025, with additional $29.8 million gross proceeds from usage of at-the-market (ATM) offering facility in October 2025Announced U.S. IND clearance and alignment with U.S ...